Keyphrases
Cardiovascular Risk
100%
GH Deficiency
100%
Growth Hormone Deficiency
100%
Plasminogen Activator inhibitor-1 (PAI-1)
75%
Tissue Plasminogen Activator (t-PA)
50%
Endothelial Function
37%
Flow-mediated Vasodilation
25%
Venous Occlusion
25%
Body Mass Index
12%
Body Composition
12%
Primary Outcome Measure
12%
Prospective Observational Study
12%
Lipid Profile
12%
Area under the Curve
12%
Cardiac Performance
12%
Comparisons with a Control
12%
Lipid Bodies
12%
Cardiovascular Morbidity
12%
Thrombolytic Potential
12%
Plasminogen Activation
12%
Function Performance
12%
Activity Value
12%
Occlusion Test
12%
Biochemistry, Genetics and Molecular Biology
Plasminogen Activator Inhibitor-1
100%
Bovine Somatotropin
100%
Growth Hormone
100%
Tissue Plasminogen Activator
66%
Vasodilatation
33%
Blood Plasma
33%
Lipid Profile
16%
Observational Study
16%
Body Mass
16%
Heart Performance
16%
Body Composition
16%
Plasminogen Activation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Risk
100%
Fibrinolytic Agent
100%
Growth Hormone Deficiency
100%
Plasminogen Activator Inhibitor 1
66%
Tissue Plasminogen Activator
44%
Vein Occlusion
22%
Observational Study
11%
Plasminogen
11%
Medicine and Dentistry
Growth Hormone Deficiency
100%
Cardiovascular Risk
100%
Plasminogen Activator Inhibitor-1
66%
Tissue Plasminogen Activator
44%
Endothelial Function
33%
Vasodilatation
22%
Vein Occlusion
22%
Study Participant
11%
Body Mass Index
11%
Observational Study
11%
Heart Performance
11%
Cardiovascular System
11%
Plasminogen Activation
11%